Recognition and management of persistent chylomicronemia: A joint expert clinical consensus by the National Lipid Association and the American Society for Preventive Cardiology
Extreme hypertriglyceridemia, defined as triglyceride (TG) levels ≥1000 mg/dL, is almost always indicative of chylomicronemia. The current diagnostic approach categorizes individuals with chylomicronemia into familial chylomicronemia syndrome (FCS; prevalence 1-10 per million), caused by the biallelic combination of pathogenic variants that impair the lipolytic action of lipoprotein lipase (LPL), or multifactorial chylomicronemia syndrome (MCS, 1 in 500). A pragmatic framework should emphasize the severity of the phenotype and the risk of complications. Therefore, we endorse the term "persistent chylomicronemia" defined as TG ≥1000 mg/dL in more than half of the measurements to encompass patients with the highest risk for pancreatitis, regardless of their genetic predisposition. We suggest classification of PC into four subtypes: 1) genetic FCS, 2) clinical FCS, 3) PC with "alarm" features, and 4) PC without alarm features. Although patients with FCS most likely have PC, the vast majority with PC do not have genetic FCS. Proposed alarm features are: (a) history of recurrent TG-induced acute pancreatitis, (b) recurrent hospitalizations for severe abdominal pain without another identified cause, (c) childhood pancreatitis, (d) family history of TG-induced pancreatitis, and/or (e) post-heparin LPL activity <20 % of normal value. Alarm features constitute the strongest risk factors for future acute pancreatitis risk. Patients with PC and alarm features have very high risk of pancreatitis, comparable to that in patients with FCS. Effective, innovative treatments for PC, like apoC-III inhibitors, have been developed. Combined with lifestyle modifications, these agents markedly lower TG levels and risk of pancreatitis in the very-high-risk groups, irrespective of the monogenic etiology. Pragmatic definitions, education, and focus on patients with PC specifically those with alarm features could help mitigate the risk of acute pancreatitis and other complications.
Authors
- Michael D. Shapiro
- Erin D. Michos (ORCID: https://orcid.org/0000-0002-5547-5084)
- Seyedmohammad Saadatagah
- Miriam Larouche (ORCID: https://orcid.org/0009-0007-2356-5396)
- Christie Mitchell Ballantyne (ORCID: https://orcid.org/0000-0002-6432-1730)
- Iftikhar J. Kullo (ORCID: https://orcid.org/0000-0002-6524-3471)
- Diane Brisson (ORCID: https://orcid.org/0000-0002-9878-4346)
- P. Barton Duell (ORCID: https://orcid.org/0000-0002-0208-5154)
- Gerald F. Watts (ORCID: https://orcid.org/0000-0003-2276-1524)
- Mohammadreza Naderian (ORCID: https://orcid.org/0000-0003-1827-3173)
- Vijay Nambi (ORCID: https://orcid.org/0000-0002-4237-0267)
- Daniel Gaudet (ORCID: https://orcid.org/0000-0002-5185-3666)
Institutions
- Université du Québec à Chicoutimi (CA)
- Michael E. DeBakey VA Medical Center (US)
- Mayo Clinic (US)
- Johns Hopkins University (US)
- Oregon Health & Science University (US)
- The University of Western Australia (AU)
- Baylor College of Medicine (US)
- Royal Perth Hospital (AU)
- Johns Hopkins Medicine (US)
- Mayo Clinic in Arizona (US)
- Wake Forest University (US)
- Université de Montréal (CA)
Publication Details
- Journal
- American Journal of Preventive Cardiology
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1016/j.ajpc.2025.100978
- Citations
- 8
- Primary Topic
- Lipid metabolism and disorders
- Type
- article
- Field-Weighted Citation Impact
- 11.11